| 000 | 00000cam 2200000zi 4500 |
| 001 | 9.965452 |
| 003 | CaOODSP |
| 005 | 20260925090529 |
| 006 | m o d f |
| 007 | cr cn||||||||| |
| 008 | 250826s2025 onca os f000 0 eng d |
| 040 | |aCaOODSP|beng|erda|cCaOODSP |
| 041 | 0 |aeng|afre |
| 043 | |an-cn--- |
| 045 | |ay1y2 |
| 086 | 1 |aH82-66/2025-PDF |
| 100 | 1 |aWladyka, Blake, |eauthor. |
| 245 | 10|aInsight into approvals, marketing, and pricing of new medicines, 2018 to 2023 / |cBlake Wladyka and Étienne Gaudette = Aperçu des approbations, de la commercialisation et des prix des nouveaux médicaments, de 2018 à 2023 / Blake Wladyka et Étienne Gaudette. |
| 246 | 11|aAperçu des approbations, de la commercialisation et des prix des nouveaux médicaments, de 2018 à 2023 |
| 264 | 1|a[Ottawa] : |bPatented Medicine Prices Review Board = Conseil d'examen du prix des médicaments brevetés, |c[2025] |
| 300 | |a1 online resource (1 page) : |bcolour illustrations |
| 336 | |atext|btxt|2rdacontent |
| 337 | |acomputer|bc|2rdamedia |
| 338 | |aonline resource|bcr|2rdacarrier |
| 500 | |a"NPDUIS, National Prescription Drug Utilization Information System." |
| 520 | |a"High-cost specialty medicines are increasingly dominating the landscape of new medicines launched in Canada and around the world. A growing share of these medicines (including biologics, orphan drugs, and oncology products) have annual treatment costs in the tens or hundreds of thousands of dollars. This study provides an overview of new medicine approvals, sales, pricing, characteristics, and access in Canada and internationally"--Objective. |
| 546 | |aText in English and French. |
| 650 | 0|aDrug approval|zCanada|vStatistics. |
| 650 | 0|aDrug approval|vStatistics. |
| 650 | 0|aDrugs|xPrices|zCanada|vStatistics. |
| 650 | 0|aDrugs|xPrices|vStatistics. |
| 650 | 0|aDrug accessibility|zCanada|vStatistics. |
| 650 | 0|aDrug accessibility|vStatistics. |
| 650 | 0|aPharmaceutical industry|zCanada|vStatistics. |
| 650 | 0|aPharmaceutical industry|vStatistics. |
| 655 | 7|aStatistics|2lcgft |
| 710 | 1 |aCanada. |bPatented Medicine Prices Review Board, |eissuing body. |
| 788 | |tInsight into approvals, marketing, and pricing of new medicines, 2018 to 2023 / |efre|w(CaOODSP)9.966259 |
| 856 | 40|qPDF|s656 KB|uhttps://publications.gc.ca/collections/collection_2026/cepmb-pmprb/H82-66-2025.pdf |
| 856 | 4 |qHTML|sN/A|uhttps://www.canada.ca/en/patented-medicine-prices-review/services/npduis/analytical-studies/posters/insight-approvals-2025poster.html |